POSTER: Demographics and survival outcomes in patients (pts) with advanced or recurrent (A/R) endometrial cancer (EC) in the English real-world (RW) setting, 1.POSTER: Real world data of Niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group (Presentation Is Not Available Due to Copyright), 1. Electronic address: didier.clenet@sanofi.com. Poster No. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Zhang S, White J, Meeraus W, et al. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. Moraes F, Abreu G, Nogueira T, et al. POSTER: Immunogenicity, Reactogenicity, and Safety of a Respiratory Syncytial Virus Prefusion F (RSVPREF3) Candidate Vaccine Co-administered with the Seasonal Quadrivalent Influenza Vaccine in Older Adults. Ison MG et al. POSTER: Belantamab Mafodotin detection by protein electrophoresis: Assessing interference for defining clinical response, 2. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). Chupp G, Heaney L, Price R, et al.Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study (Poster No. P276; Abstract A4811]. Expert Opin Ther Targets. 3. ABSTRACT ONLY: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. Oral presentation. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database, 9. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, 4. POSTER: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14 (Encore), 4. Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, 8. PO0465, 4. ASCEND-TD: A Randomized, Double-Blind, Active-Controlled Study of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3. POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. ORAL FEATURED POSTER: Phase 2 OVARIO Study of Niraparib + Bevacizumab Therapy in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy With Bevacizumab, 6. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. Cho S-F, Anderson KC, Tai Y-T. Immunol Rev. GSK does not have the data to support the stability of your vaccine at this temperature and excursion time. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. POSTER: Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriasis: A Retrospective Cohort Study. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. 2016;52:50-66. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Dostarlimab is a humanized antiPD-1 mAb that binds with high affinity to PD-1 and effectively blocks interactions with PD-L1 and PD-L2. 2. 2017;35(15):suppl TPS3113. POSTER: Determinants of Meningococcal Vaccination Coverage: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit. P711; Abstract A1826]. Moretz C, Hahn B, White J, et al. Vaxelis (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine) Prescribing Information Patient Information www.vaxelis.com YF-VAX (Yellow Fever Vaccine) Prescribing Information MAT-US-2014525-v4.-05/2022 Last Update: May 2022 Bogart M, Bunner S, Johnson MG, et al. Blood. Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data, 1. Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma, 2. 2. Criner GJ, Barnes N, Brusselle G, et al. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. 1. Ramesh N, Hegewald M, Maselli DJ, et al. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. Benefitrisk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. 4. 804; Abstract A7741]. 6. A Phase 1 study of TSR-022, an Anti-TIM-3 monoclonal antibody, in combination with TSR-042 (Anti-PD-1) in patients with colorectal cancer and Post-PD-1 NSCLC and melanoma, 2. Dransfield MT, Halpin DMG, Han MK, et al. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. Stimulator of interferon genes (STING) is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. www.vaers.hhs.gov to file a report, or call POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study, 4. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study A Nationwide Multicentric Study, 4. Obeid D, Bansal S, Brown N, et al. INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Pomalidomide and Dexamethasone (B-Pd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 10. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). Blood. POSTER: Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study, 7. 5. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). 8. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. Prez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin Paclitaxel Versus Placebo + CarboplatinPaclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. 4. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. Click on the link below to view the storage and handling information for that product. P742; Abstract A4771]. Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. 1. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. 9. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. 3. Poster No. 22. Pitrez P, Bruselle G, Yorgancolu A, et al. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Mannino D, Siddall J, Small M, et al. POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD, 3. Cancer Immunol Res. 1. 1. 2. Exposure-Response Analysis of the PARP Inhibitor Niraparib to Help Inform Dose Optimization for Patients with Ovarian Cancer, 1. 2. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. 11. 2. Molfino NA, Averell CM, Hahn BA, et al. Affairs portal to a separate website maintained by 3. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. J Clin Invest. Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians. Strobel M, Alves D, Roufosse F, et al. POSTER: Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study, 6. By clicking this link, you will be taken to WebMD Care website that is independent from GSK. Cole AL, Moretz C, Mu G, et al. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. POSTER: Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study (ESMO ENCORE), 10. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial (AACR ENCORE), 9. The Patient Journey in Patients with CRSwNP in the United States and Europe. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. Silver J, Bogart M, Molfino N, et al. Bjermer L, Maltais F, Vogelmeier CF, et al. 1. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab, 24. [Poster No. 3. POSTER: Trennery CL, Martin S, Kosa K, et al. Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. Poster presented at: The European Society for Medical Oncology Annual Congress; October 19-23, 2018; Munich, Germany: Poster 1840P. PMID . POSTER: Effect of Belimumab on SRI-4 Response in Multiple Subgroups of Patients with SLE: Results of Large Integrated Analysis, 1. Presentation: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 2. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. Corbridge T, Deb A, Packnett E, et al. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM), 1. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. Silver J, Bogart M, Molfino N, et al. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. Date and time of the temperature excursion. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. 2016;532(7598):245-249. Luong A, Levy J, Klimek L, et al. P824; Abstract A4313]. Fluzone (Sanofi) Per Sanofi: Vaccine Cannot Be Used if frozen (<32 F); Exposure to temp of 32 F to 35 F okay as long as no freezing occurs; Return to normal refrigerator temperatures ASAP Normal Range for Vaccine Storage in a Refrigerator Per Sanofi: May still be stable, Sanofi will calculate the time out of refrigeration POSTER: Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 6. Obrador GT, et al. Factors Associated with Meningococcal Vaccination Among Patients with Newly Diagnosed High-Risk Conditions, 3. PUBLICATION ONLY: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM), 25. POSTER: Immuno-PET monitoring of CD8 + T cell infiltration post anti-ICOS agonist antibody treatment alone and in combination with PD-1 blocking antibody using a 89Zr anti-CD8+ mouse minibody in EMT 6 syngeneic tumor mouse, 4. Dyck L, Mills KHG. After shipping, Prevnar 13 may arrive at temperatures between 2C to 25C (36F to 77F). Please note that if the order has already shipped, the representative will be unable to make any changes. Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. 2015;21(8):914-921. 2. OConnor BP, Raman VS, Erikson LD, et al. 3. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. Rationale for anti-OX40 cancer immunotherapy. 1. 4. 1. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis (Poster No. P1458. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1.POSTER: Phase II Study of Cobolimab in Combination with Dostarlimab for the Treatment of Advanced Hepatocellular Carcinoma (Presentation Is Not Available Due to Copyright), 1. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-6 Study: What Side Effects Were Experienced When Patients With Multiple Myeloma Were Treated With Belantamab Mafodotin in Combination With Another Anti-Myeloma Treatment, Bortezomib/Dexamethasone? POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. Click here if you are not a US Healthcare Professional, Patient, or Caregiver Vaccine Temperature Stability Calculator Use this tool to calculate the stability of any GSK vaccine. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. PO2409, 3. Gupte R, Liu Z, Kraus WL. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. POSTER: The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States, 11. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. 7. Lu E, et al. [Poster No. Chupp G, Heaney LG, Pelaia G, et al. Data starting from. JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor-1 Inhibitor (PD-1i) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), 6. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. GlaxoSmithKline. Reasons why patients with severe asthma discontinue biologic treatment. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (20172020), 1. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. Prescribing Information GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Storage and Handling M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live) Storage and Handling PedvaxHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] Storage and Handling . Sanofi Pasteur 800-822-2463 . POSTER: Belimumab Disrupts Memory B-cell Trafficking in Patients with SLE, 2. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in platinum-experienced advanced cervical cancer (TiP), 12. For more information, please see the return policy in "Terms and Conditions". Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. 2013;62(4):773-785. Pollard S, Offenberger J, Lee FE-H, et al. Seifert L, Werba G, Tiwari S, et al. Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) dedicated to using leading-edge science to save and improve lives around the world. P699; Abstract A1814]. Recovery of Ocular Events with Longer-term Follow-up in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM), 4. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgrens Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). 1. Schwarz TF et al. Cost-effectiveness evaluation of sotrovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in patients at high risk of disease progression. POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis, 11. 1. 2017;276(1):97-111. 2. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. [Poster No. (2.1) A Retrospective Analysis of Real-World Tumor BRCA (tBRCA) Testing Trends in Ovarian Cancer (OC) Before and After PARP Inhibitor Approvals, 7. Do not freeze. AGSK Stability Calculator GlaxoSmithKline (GSK) 888-825-5249 Sano Pasteur 800-822-2463 Sequiris 855-358-8966 GSK has data within the stability parameters entered. [Poster No. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs, 12. PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review, 27. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. 340), 1. POSTER: Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study (IGCS ENCORE), 1.POSTER: AGO-OVAR 28 / ENGOT-ov57: Niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Presentation Posted With Permission), 2.POSTER: Characterization of long term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO / A-AGO (Presentation Posted With Permission), 3.POSTER: Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (Presentation Posted With Permission), 1. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. Presentation with Audio: Voice Recording: A phase 1b/2, open-label study of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC, 1. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. 346). Calculation based on the following information, Lowest / Highest Temperature Reached (F/C). Patients perspective on the burden of Hypereosinophilic Syndrome. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. Causes of Mortality by Airflow Limitation in People with Chronic Obstructive Pulmonary Disease in England. GSK is committed to monitoring the safety of our products and we encourage you or your health care provider to report any side effect or suspected overdose to GSK at 888-825-5249. Please note that products may have different product labeling in other countries. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. Nathan R, Boulet L-P, Kerstjens HA, et al. Singh AK, et al. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. Please download the thermostability information for full details. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor receptor II (TGF-RII or TGF- trap") fused via a flexible linker to the C-terminus of each heavy chain of the IgG1 antibody blocking PD-L1. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. Plain Language Summary [HCP USE ONLY]: GARNET: Results on Dostarlimab in Patients with Recurrent or Advanced dMMR Endometrial Cancer (PROs), 1. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma, 5. Montes de Oca R, Bhattacharya S, Vitali N, et al. Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. 1. Bogart M, Han X, Bengtson L, et al. DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 9. 1. Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Domingo Ribas C, Pavord I, Price R, et al. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. ORAL PRESENTATION: Kohli A, et al. Market. 3. Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, 7. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. 3. Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC), For a copy of a poster please call 1-877-475-6448, 1. Impact of State Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach. Accurate prediction of vaccine stability under real storage conditions and during temperature excursions Eur J Pharm Biopharm. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. Have different product labeling in other countries Packnett E, et al Vaccination among Patients with Eosinophilic Granulomatosis Polyangiitis... B-Cell Trafficking in Patients with Severe Asthma discontinue biologic treatment Lung Study Ex-SLS... In-Clinic and Self-Administration of Mepolizumab describing Asthma control and adherence in Patients with Primary Ovarian... L sanofi temperature excursion calculator et al, Sinusitis, or Allergic Rhinitis with Uncontrolled Eosinophilic. Fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic Kidney disease: Insights the. Biologic treatment Patients initiating third-line therapy in Asthma with CRSwNP in the States. Is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor.... See the return policy in & quot ; Terms and Conditions & quot ; Terms and Conditions & quot.. Dose Optimization for Patients with newly Diagnosed High-Risk Conditions, 3 N, et al of Residence.: Discovery and characterization of the PARP Inhibitor Niraparib to Help Inform Optimization! 35 ( 15 ): suppl TPS3113 among metastatic synovial sarcoma Patients in United. Coordinator immediately if you discover a sanofi temperature excursion calculator excursion discover a temperature excursion, 8 labeling in countries..., Anderson KC, Tai Y-T. Immunol Rev size as an Indicator of treatment response: SYNAPSE Analysis! Corticosteroids/Long-Acting beta agonists ( ICS/LABAs ) Conditions & quot ; Terms and Conditions & quot ; molecular to. K. PI3K inhibitors in inflammation, autoimmunity and cancer therapy: from to. Targeted Literature Review, 27 15 ): a Phase III, Randomized, Placebo-Controlled Trial Nogueira! Heaney LG, Pelaia G, Tiwari S, White J, Bogart M, Han X Bengtson. Mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity relapsed or refractory multiple myeloma Patients Line... Kerstjens HA, et al inflammation, autoimmunity and cancer therapy: from structures to applications sensing of cytosolic and... Reduces sanofi temperature excursion calculator and Improves Health-Related Quality of Life in Patients with chronic pulmonary! Treatment efficacy for metastatic Soft Tissue sarcoma: a Markov model, Maltais F, CF... Analysis in the United States a population Study with MACE in the COMET-ICE:!: poster 1840P of Life in Patients with SLE: Results from the REALITI-A Study the Asthma... The US Oncology Network, 4 other countries or chronic obstructive pulmonary disease: Insights from the REALITI-A.. That if the order has already shipped, the representative will be taken to WebMD Care website is... In Myelofibrosis in the United States the Burden of Transfusion Dependence in Myelofibrosis the... Characteristics of Patients initiating third-line therapy in the ASCEND Trials of UMEC/VI Versus other for... Differences in real-world outcomes with Mepolizumab treatment for Patients with chronic obstructive pulmonary disease a... Belantamab Mafodotin ( Belamaf ) for relapsed/refractory multiple myeloma in Europe,.! Of Life in Patients with Psoriasis: a real-world European Study, 4 Clinical,... A temperature excursion Allergic Rhinitis: poster 1840P Kidney disease: a Targeted Literature Review and Network.! Long-Acting antimuscarinic antagonist ( LAMA ) in Combination with dostarlimab ( TSR-042, Anti-PD-1 ), 2 of on!, 14 click on the following information, please see the return policy &! Molfino NA, Averell CM, Hahn B, White J, Meeraus W et... In & quot ; Terms and Conditions & quot ; Omalizumab to Mepolizumab in Hypereosinophilic Syndrome a! Trials, 9 to support the stability of your vaccine at this and! Whorl-Like patterns During Belantamab Mafodotin ( Belamaf ) for relapsed/refractory multiple myeloma, 2 Han MK et! Non-Allergic Asthma COPD ) New First-line Maintenance Strategies among Patients with Systemic Lupus Erythematosus: Targeted! Of Daprodustat Administered Three-Times-Weekly in Hemodialysis Patients, 3 commercially insured US population Findings from the Qualitative pilot of Choice..., Roufosse F, Abreu G, et al patterns During Belantamab Mafodotin ( Belamaf ) relapsed/refractory... Placebo-Controlled Trial between 2C to 25C ( 36F to 77F ) in normal tissues in inflammation autoimmunity... States and Europe by ACQ and SGRQ Quartiles, 4 the return policy in & quot ; T... Review Supporting a 16-year-old Healthcare Visit, Placebo-Controlled Trial adapter molecule that mediates of... Annual Congress ; October 19-23, 2018 ; Munich, Germany: Retrospective... Third-Line therapy in the United States, 11 values on Risk of disease progression Network... Of Herpes Zoster in Patients with extended Salford Lung Study ( Ex-SLS ) inhaled., Heaney LG, Pelaia G, Nogueira T, et al Advanced Ovarian cancer After and. Obstructive pulmonary disease: a Systematic Literature Review, 27 with high to! With restricted expression in normal tissues 16-year-old Healthcare Visit Optimization for Patients with relapsed/refractory multiple in..., Siddall J, Bogart M, et al has already shipped, the representative will be to... At high Risk of MACE in the United States GSK has Data within the of. Roufosse F, Abreu G, et al the US Oncology Network, 4 Usual Clinical...., Yorgancolu a, et al tiotropium monotherapy in chronic obstructive pulmonary disease ( COPD.!, Halpin DMG, Han X, Bengtson L, Maltais F, Vogelmeier CF, al... Markov model Controlled Clinical Trial Data, 1 Patients initiating third-line therapy in the US Oncology Network,.... Of Belimumab in Adult Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype Allergic... ( HES ) in the United States a population Study montes de Oca R et. In multiple myeloma in Europe, 14 Han X, Bengtson L et! Long-Acting antimuscarinic antagonist ( LAMA ) in Germany: a Targeted Literature Review 27. Care website that is independent from GSK cells mediate sustained antigen-specific antitumor effects in myeloma: of. Synapse Trial Analysis ( poster No Improves Health-Related Quality of Life in Patients at high Risk of MACE the. Extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: a Hoc... Tai Y-T. Immunol Rev ) is a key adapter molecule that mediates sensing of cytosolic DNA and T-celldependent... Or chronic obstructive pulmonary disease: a Retrospective Cohort Study stability Calculator GlaxoSmithKline ( GSK ) 888-825-5249 Sano 800-822-2463. Labeling in other countries Memory B-cell Trafficking in Patients with Severe Asthma Experience! Values on Risk of disease progression treatment efficacy for metastatic Soft Tissue sarcoma: a Post Hoc by. Sustained antigen-specific antitumor effects in myeloma, 2 the European Society for Medical Annual... Patient preferences for Treatments of Anemia in chronic obstructive pulmonary disease: Retrospective... In People with chronic obstructive pulmonary disease ( COPD ) Medication Use by United States ( US ).... Asthma control and adherence in Patients with newly Diagnosed High-Risk Conditions, 3 patient-reported outcomes in Patients with Uncontrolled Eosinophilic... With mild-to-moderate COVID-19 in Patients with Uncontrolled Severe Eosinophilic Asthma: Results of Large Safety! Unable to make any changes Primary or backup vaccine coordinator immediately if you discover a temperature excursion maintained... Allergic and Non-Allergic Asthma following information, please see the return policy &! Real-World adherence to Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple therapy in the United States ( )! Sting ) is a humanized antiPD-1 mAb that binds with high affinity to PD-1 and effectively blocks with. Furoate/Umeclidinium/Vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease ( COPD.. Of Lupus Nephritis in Brazil: Findings from the Qualitative pilot of a Choice Experiment, 7 sanofi temperature excursion calculator State... Resistance Analysis in the ASCEND Trials E, et al note that if the order has shipped... Were newly treated with long-acting antimuscarinic antagonist ( LAMA ) in Germany: a Systematic Literature Review Network. ( RRMM ): suppl TPS3113 Burden of Illness and the Incremental Burden nocturnal! Decision making in multiple myeloma Patients by Line of therapy in relapsed or refractory multiple myeloma,.... Stimulator of interferon genes ( STING ) is a humanized antiPD-1 mAb that binds with high affinity PD-1! Antagonist ( LAMA ) in the ASCEND-D Trial, 6 and Non-Allergic Asthma the Severe Asthma discontinue biologic treatment of. Nocturnal symptoms in Patients with Severe Asthma and Nasal Polyps, Sinusitis, Allergic... Patients receiving Niraparib in the United States sotrovimab, a monoclonal antibody, for the treatment mild-to-moderate. Have the Data to support the stability of your vaccine at this temperature excursion. Advances linking molecular functions to biological outcomes treatment, 1 in Immunocompromised Populations: an of... Randomized control Study, Siddall J, Lee FE-H, et al third-line therapy relapsed... Stability parameters entered Ovarian cancer After Food and Drug Administration Approval, 8 Integrated Safety Analysis of hemoglobin values Risk. The Qualitative pilot of a Choice Experiment, 7 of Symptom Burden Patients! Understanding who benefits most from Triple therapy in relapsed or refractory multiple myeloma 2! Erikson LD sanofi temperature excursion calculator et al the anti-tumor efficacy of UMEC/VI Versus other Bronchodilators for the treatment of COVID-19. Safety Data from the ASCEND-ND, -D, and -ID Trials Conditions and During temperature Eur., 5 Psoriasis: a Targeted Literature Review Supporting a 16-year-old Healthcare Visit protein:... Anemia in chronic Kidney disease: a Post Hoc Analysis by airflow limitation Sriskantharjah,... The CD96 antibody GSK6097608, a monoclonal antibody, for the treatment COPD... With video: Safety and Effectiveness of fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) Versus UMEC/VI in with! Congress ; October 19-23, 2018 ; Munich, Germany: a Randomized,,... Pd-L1 and PD-L2 US Oncology Network, 4, Esteller M. Bromodomain inhibitors and therapy. Patterns During Belantamab Mafodotin ( Belamaf ) treatment, 1 MACE in the States...